Skip to main content



Page 5 of 15

  1. Content type: Research

    Cerebrospinal fluid (CSF) neurofilament light (NfL) is a reliable marker of neuro-axonal damage in different neurological disorders that is related to disease severity. To date, all recent studies performed in...

    Authors: Lorenzo Gaetani, Kina Höglund, Lucilla Parnetti, Fani Pujol-Calderon, Bruno Becker, Paolo Eusebi, Paola Sarchielli, Paolo Calabresi, Massimiliano Di Filippo, Henrik Zetterberg and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2018 10:8

    Published on:

  2. Content type: Research

    In this paper, we describe the clinical and neuropathological findings of nine members of the Belgian progranulin gene (GRN) founder family. In this family, the loss-of-function mutation IVS1 + 5G > C was identif...

    Authors: Anne Sieben, Sara Van Mossevelde, Eline Wauters, Sebastiaan Engelborghs, Julie van der Zee, Tim Van Langenhove, Patrick Santens, Marleen Praet, Paul Boon, Marijke Miatton, Sofie Van Hoecke, Mathieu Vandenbulcke, Rik Vandenberghe, Patrick Cras, Marc Cruts, Peter Paul De Deyn…

    Citation: Alzheimer's Research & Therapy 2018 10:7

    Published on:

  3. Content type: Research

    Cognitive screeners are imperative for early diagnosis of dementia. The Visual Cognitive Assessment Test (VCAT) is a language-neutral, visual-based test which has proven useful for a multilingual population in...

    Authors: Levinia Lim, Tze Pin Ng, Anam Paulus Ong, Maw Pin Tan, Alvin Rae Cenina, Qi Gao, Adeline Ng and Nagaendran Kandiah

    Citation: Alzheimer's Research & Therapy 2018 10:6

    Published on:

  4. Content type: Research

    We investigated whether a panel of 12 potential novel biomarkers consisting of proteins involved in synapse functioning and immunity would be able to distinguish patients with Alzheimer’s disease (AD) and pati...

    Authors: Flora H. Duits, Gunnar Brinkmalm, Charlotte E. Teunissen, Ann Brinkmalm, Philip Scheltens, Wiesje M. Van der Flier, Henrik Zetterberg and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2018 10:5

    Published on:

  5. Content type: Research

    Given the complex and progressive nature of Alzheimer’s disease (AD), a precision medicine approach for diagnosis and treatment requires the identification of patient subgroups with biomedically distinct and a...

    Authors: Nophar Geifman, Richard E. Kennedy, Lon S. Schneider, Iain Buchan and Roberta Diaz Brinton

    Citation: Alzheimer's Research & Therapy 2018 10:4

    Published on:

  6. Content type: Research

    Neurofilament light chain protein (NfL) is a surrogate biomarker of neurodegeneration that has never been systematically tested, either alone or in combination with other biomarkers, in atypical/rapidly progre...

    Authors: Samir Abu-Rumeileh, Sabina Capellari, Michelangelo Stanzani-Maserati, Barbara Polischi, Paolo Martinelli, Paola Caroppo, Anna Ladogana and Piero Parchi

    Citation: Alzheimer's Research & Therapy 2018 10:3

    Published on:

  7. Content type: Research

    The MAPT c.1216C > T (p.Arg406Trp; R406W) mutation is a known cause of frontotemporal dementia with Parkinsonism linked to chromosome 17 tau with Alzheimer’s disease-like clinical features.

    Authors: Emil Ygland, Danielle van Westen, Elisabet Englund, Rosa Rademakers, Zbigniew K. Wszolek, Karin Nilsson, Christer Nilsson, Maria Landqvist Waldö, Irina Alafuzoff, Oskar Hansson, Lars Gustafson and Andreas Puschmann

    Citation: Alzheimer's Research & Therapy 2018 10:2

    Published on:

  8. Content type: Research

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the elderly population. In this study, we used the APP/PS1 transgenic mouse model to explore the fe...

    Authors: Jelle Praet, Nikolay V. Manyakov, Leacky Muchene, Zhenhua Mai, Vasilis Terzopoulos, Steve de Backer, An Torremans, Pieter-Jan Guns, Tom Van De Casteele, Astrid Bottelbergs, Bianca Van Broeck, Jan Sijbers, Dirk Smeets, Ziv Shkedy, Luc Bijnens, Darrel J. Pemberton…

    Citation: Alzheimer's Research & Therapy 2018 10:1

    Published on:

  9. Content type: Research

    Cerebrovascular disease (CVD) and amyloid-β (Aβ) often coexist, but their influence on neurodegeneration and cognition in predementia stages remains unclear. We investigated the association between CVD and Aβ ...

    Authors: Isabelle Bos, Frans R. Verhey, Inez H.G.B. Ramakers, Heidi I. L. Jacobs, Hilkka Soininen, Yvonne Freund-Levi, Harald Hampel, Magda Tsolaki, Åsa K. Wallin, Mark A. van Buchem, Ania Oleksik, Marcel M. Verbeek, Marcel Olde Rikkert, Wiesje M. van der Flier, Philip Scheltens, Pauline Aalten…

    Citation: Alzheimer's Research & Therapy 2017 9:101

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2018 10:56

  10. Content type: Research

    Little is known about factors influencing progression from mild cognitive impairment to Alzheimer’s dementia. A potential role of environmental chemicals and specifically of selenium, a trace element of nutrit...

    Authors: Marco Vinceti, Annalisa Chiari, Marcel Eichmüller, Kenneth J. Rothman, Tommaso Filippini, Carlotta Malagoli, Jennifer Weuve, Manuela Tondelli, Giovanna Zamboni, Paolo F. Nichelli and Bernhard Michalke

    Citation: Alzheimer's Research & Therapy 2017 9:100

    Published on:

  11. Content type: Research

    In patients with amyloid-positive mild cognitive impairment (MCI), neurodegenerative biomarkers such as medial temporal lobe atrophy (MTA) are useful to predict disease progression to dementia. Although poster...

    Authors: Jung-Min Pyun, Young Ho Park, Hang-Rai Kim, Jeewon Suh, Min Ju Kang, Beom Joon Kim, Young Chul Youn, Jae-Won Jang and SangYun Kim

    Citation: Alzheimer's Research & Therapy 2017 9:99

    Published on:

  12. Content type: Research

    Soluble amyloid-β (Aβ) oligomers are the major toxic substances associated with the pathology of Alzheimer’s disease (AD). The ability to measure Aβ oligomer levels in the blood would provide simple and minima...

    Authors: Min Jeong Wang, SangHak Yi, Jee-young Han, So Young Park, Jae-Won Jang, In Kook Chun, Sang Eun Kim, Byoung Sub Lee, Gwang Je Kim, Ji Sun Yu, Kuntaek Lim, Sung Min Kang, Young Ho Park, Young Chul Youn, Seong Soo A. An and SangYun Kim

    Citation: Alzheimer's Research & Therapy 2017 9:98

    Published on:

  13. Content type: Review

    The progress we have made in understanding Alzheimer’s disease (AD) pathogenesis has led to the identification of several novel pathways and potential therapeutic targets. Rho GTPases have been implicated as c...

    Authors: Byron J. Aguilar, Yi Zhu and Qun Lu

    Citation: Alzheimer's Research & Therapy 2017 9:97

    Published on:

  14. Content type: Research

    The aim of this study was to compare the binding properties of several tau positron emission tomography tracers—THK5117, THK5351, T807 (also known as AV1451; flortaucipir), and PBB3—head to head in the same hu...

    Authors: Laetitia Lemoine, Per-Göran Gillberg, Marie Svedberg, Vladimir Stepanov, Zhisheng Jia, Jinghai Huang, Sangram Nag, He Tian, Bernardino Ghetti, Nobuyuki Okamura, Makoto Higuchi, Christer Halldin and Agneta Nordberg

    Citation: Alzheimer's Research & Therapy 2017 9:96

    Published on:

  15. Content type: Research

    Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safet...

    Authors: Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli…

    Citation: Alzheimer's Research & Therapy 2017 9:95

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2018 10:99

  16. Content type: Research

    Biomarkers such as amyloid imaging are increasingly used for diagnosis in the early stages of Alzheimer’s disease. Very few studies have examined this from the perspective of the patient. To date, there is onl...

    Authors: Gwendolien Vanderschaeghe, Jolien Schaeverbeke, Rose Bruffaerts, Rik Vandenberghe and Kris Dierickx

    Citation: Alzheimer's Research & Therapy 2017 9:92

    Published on:

  17. Content type: Research

    Alzheimer’s disease (AD) is the most common type of dementia, affecting one in eight adults over 65 years of age. The majority of AD cases are sporadic, with unknown etiology, and only 5% of all patients with ...

    Authors: Anna Ochalek, Balázs Mihalik, Hasan X. Avci, Abinaya Chandrasekaran, Annamária Téglási, István Bock, Maria Lo Giudice, Zsuzsanna Táncos, Kinga Molnár, Lajos László, Jørgen E. Nielsen, Bjørn Holst, Kristine Freude, Poul Hyttel, Julianna Kobolák and András Dinnyés

    Citation: Alzheimer's Research & Therapy 2017 9:90

    Published on:

  18. Content type: Research

    Clusterin and beta-amyloid (Aβ) are involved in the pathogenesis of Alzheimer’s disease (AD). The clinical significance of plasma clusterin and Aβ in AD progression remains controversial.

    Authors: Jung-Lung Hsu, Wei-Ju Lee, Yi-Chu Liao, Shuu-Jiun Wang and Jong-Ling Fuh

    Citation: Alzheimer's Research & Therapy 2017 9:91

    Published on:

  19. Content type: Research

    Minimally invasive specific biomarkers of neurodegenerative diseases (NDs) would facilitate patient selection and disease progression monitoring. We describe the assessment of circulating brain-enriched microR...

    Authors: Kira S. Sheinerman, Jon B. Toledo, Vladimir G. Tsivinsky, David Irwin, Murray Grossman, Daniel Weintraub, Howard I. Hurtig, Alice Chen-Plotkin, David A. Wolk, Leo F. McCluskey, Lauren B. Elman, John Q. Trojanowski and Samuil R. Umansky

    Citation: Alzheimer's Research & Therapy 2017 9:89

    Published on:

  20. Content type: Research

    African Americans have been reported to have a higher prevalence of Alzheimer’s disease (AD) than Caucasians, but etiology-specific AD biomarkers have not been systematically analyzed in older African American...

    Authors: Jennifer C. Howell, Kelly D. Watts, Monica W. Parker, Junjie Wu, Alexander Kollhoff, Thomas S. Wingo, Cornelya D. Dorbin, Deqiang Qiu and William T. Hu

    Citation: Alzheimer's Research & Therapy 2017 9:88

    Published on:

  21. Content type: Commentary

    This commentary discusses the implications of disease-modifying treatments for Alzheimer’s disease which seem likely to appear in the next few years and results from a meeting of British experts in neurodegene...

    Authors: Craig W. Ritchie, Tom C. Russ, Sube Banerjee, Bob Barber, Andrew Boaden, Nick C. Fox, Clive Holmes, Jeremy D. Isaacs, Ira Leroi, Simon Lovestone, Matt Norton, John O’Brien, Jim Pearson, Richard Perry, James Pickett, Adam D. Waldman…

    Citation: Alzheimer's Research & Therapy 2017 9:85

    Published on:

    The Correction to this article has been published in Alzheimer's Research & Therapy 2018 10:73

  22. Content type: Research

    From earlier studies it is known that the APOE ε2/ε3/ε4 polymorphism modulates the concentrations of cerebrospinal fluid (CSF) beta-amyloid1–42 (Aβ42) in patients with cognitive decline due to Alzheimer’s disease...

    Authors: Ronald Lautner, Philip S. Insel, Tobias Skillbäck, Bob Olsson, Mikael Landén, Giovanni B. Frisoni, Sanna-Kaisa Herukka, Harald Hampel, Anders Wallin, Lennart Minthon, Oskar Hansson, Kaj Blennow, Niklas Mattsson and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2017 9:87

    Published on:

  23. Content type: Research

    A reliable blood-based assay is required to properly diagnose and monitor Alzheimer’s disease (AD). Many attempts have been made to develop such a diagnostic tool by measuring amyloid-β oligomers (AβOs) in the...

    Authors: Seong Soo A. An, Byoung-sub Lee, Ji Sun Yu, Kuntaek Lim, Gwang Je Kim, Ryan Lee, Shinwon Kim, Sungmin Kang, Young Ho Park, Min Jeong Wang, Young Soon Yang, Young Chul Youn and SangYun Kim

    Citation: Alzheimer's Research & Therapy 2017 9:86

    Published on:

  24. Content type: Research

    The progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal compleme...

    Authors: Lutz Frölich, Oliver Peters, Piotr Lewczuk, Oliver Gruber, Stefan J. Teipel, Hermann J. Gertz, Holger Jahn, Frank Jessen, Alexander Kurz, Christian Luckhaus, Michael Hüll, Johannes Pantel, Friedel M. Reischies, Johannes Schröder, Michael Wagner, Otto Rienhoff…

    Citation: Alzheimer's Research & Therapy 2017 9:84

    Published on:

  25. Content type: Review

    Brain lesions in Alzheimer’s disease (AD) are characterized by Aβ accumulation, neurofibrillary tangles, and synaptic and neuronal vanishing. According to the amyloid cascade hypothesis, Aβ1-42 oligomers could...

    Authors: Jacques Hugon, François Mouton-Liger, Julien Dumurgier and Claire Paquet

    Citation: Alzheimer's Research & Therapy 2017 9:83

    Published on:

  26. Content type: Review

    Gene suppression approaches have emerged over the last 20 years as a novel therapeutic approach for the treatment of neurodegenerative diseases. These include RNA interference and anti-sense oligonucleotides, ...

    Authors: Rhia Ghosh and Sarah J. Tabrizi

    Citation: Alzheimer's Research & Therapy 2017 9:82

    Published on:

  27. Content type: Research

    Research has revealed that manifest Alzheimer’s disease (AD) dementia is preceded by preclinical and prodromal phases during which pathology is accumulating but function remains intact. This understanding and ...

    Authors: Michelle M. Nuño, Daniel L. Gillen, Kulwant K. Dosanjh, Jenny Brook, David Elashoff, John M. Ringman and Joshua D. Grill

    Citation: Alzheimer's Research & Therapy 2017 9:81

    Published on:

  28. Content type: Research

    The deposition of neurotoxic amyloid-β (Aβ) peptides in plaques in the brain parenchyma and in cerebral blood vessels is considered to be a key event in Alzheimer’s disease (AD) pathogenesis. Although the pres...

    Authors: Oliver Wirths, Susanne Walter, Inga Kraus, Hans W. Klafki, Martina Stazi, Timo J. Oberstein, Jorge Ghiso, Jens Wiltfang, Thomas A. Bayer and Sascha Weggen

    Citation: Alzheimer's Research & Therapy 2017 9:80

    Published on:

  29. Content type: Research

    Tauopathies represent heterogeneous groups of neurodegenerative diseases that are characterised by abnormal deposition of the microtubule-associated protein tau. Alzheimer’s disease is the most prevalent tauop...

    Authors: Radana Karlíková, Kateřina Mičová, Lukáš Najdekr, Alžběta Gardlo, Tomáš Adam, Petra Majerová, David Friedecký and Andrej Kováč

    Citation: Alzheimer's Research & Therapy 2017 9:78

    Published on:

  30. Content type: Research

    The choice and appropriate use of animal models in drug discovery for Alzheimer’s disease (AD) is pivotal to successful clinical translation of novel therapeutics, yet true alignment of research is challenging...

    Authors: Thomas Blackmore, Soraya Meftah, Tracey Karen Murray, Peter James Craig, Anthony Blockeel, Keith Phillips, Brian Eastwood, Michael J. O’Neill, Hugh Marston, Zeshan Ahmed, Gary Gilmour and Francois Gastambide

    Citation: Alzheimer's Research & Therapy 2017 9:77

    Published on:

  31. Content type: Research

    Alzheimer’s disease (AD) progression varies substantially among patients, hindering calculation of residual total life expectancy (TLE) and its decomposition into disability-free life expectancy (DFLE) and dis...

    Authors: Eric Stallard, Bruce Kinosian and Yaakov Stern

    Citation: Alzheimer's Research & Therapy 2017 9:75

    Published on:

  32. Content type: Research

    Dysfunction of the serotonergic (5-HTergic) system has been implicated in the cognitive and behavioural symptoms of Alzheimer’s disease (AD). Accumulation of toxic amyloid-β (Aβ) species is a hallmark of AD an...

    Authors: Christian Ulrich von Linstow, Jonas Waider, Manuela Grebing, Athanasios Metaxas, Klaus Peter Lesch and Bente Finsen

    Citation: Alzheimer's Research & Therapy 2017 9:74

    Published on:

  33. Content type: Research

    Amyloid pathology in subjects with mild cognitive impairment (MCI) is an important risk factor for progression to dementia due to Alzheimer’s disease. Predicting the onset of dementia is challenging even in th...

    Authors: Mara ten Kate, Frederik Barkhof, Pieter Jelle Visser, Charlotte E. Teunissen, Philip Scheltens, Wiesje M. van der Flier and Betty M. Tijms

    Citation: Alzheimer's Research & Therapy 2017 9:73

    Published on:

  34. Content type: Research

    Alzheimer’s disease (AD) impacts men and women differently, but the effect of sex on predementia stages is unclear. The objective of this study was to examine whether sex moderates the impact of florbetapir po...

    Authors: Jessica Z. K. Caldwell, Jody-Lynn Berg, Jeffrey L. Cummings and Sarah J. Banks

    Citation: Alzheimer's Research & Therapy 2017 9:72

    Published on:

  35. Content type: Review

    Due to the progressive aging of the population, Alzheimer’s disease (AD) is becoming a healthcare burden of epidemic proportions for which there is currently no cure. Disappointing results from clinical trials...

    Authors: Marta Crous-Bou, Carolina Minguillón, Nina Gramunt and José Luis Molinuevo

    Citation: Alzheimer's Research & Therapy 2017 9:71

    Published on:

  36. Content type: Research

    Polyunsaturated fatty acids play a crucial role in neuronal function, and the modification of these compounds in the brain could have an impact on neurodegenerative diseases such as Alzheimer’s disease. Despit...

    Authors: Mélanie H. Thomas, Cédric Paris, Mylène Magnien, Julie Colin, Sandra Pelleïeux, Florence Coste, Marie-Christine Escanyé, Thierry Pillot and Jean-Luc Olivier

    Citation: Alzheimer's Research & Therapy 2017 9:69

    Published on:

  37. Content type: Research

    The natural history and disease mechanisms of Alzheimer’s disease and related disorders (ADRD) are still poorly understood. Very few resources are available to scrutinise patients as early as needed and to use...

    Authors: Carole Dufouil, Bruno Dubois, Bruno Vellas, Florence Pasquier, Frédéric Blanc, Jacques Hugon, Olivier Hanon, Jean-François Dartigues, Sandrine Harston, Audrey Gabelle, Mathieu Ceccaldi, Olivier Beauchet, Pierre Krolak-Salmon, Renaud David, Olivier Rouaud, Olivier Godefroy…

    Citation: Alzheimer's Research & Therapy 2017 9:67

    Published on:

  38. Content type: Research

    β-Amyloid (Aβ) peptide is believed to play a pivotal role in the development of Alzheimer’s disease. Passive immunization with anti-Aβ monoclonal antibodies may facilitate the clearance of Aβ in the brain and ...

    Authors: Alexey Teplyakov, Galina Obmolova and Gary L. Gilliland

    Citation: Alzheimer's Research & Therapy 2017 9:66

    Published on:

  39. Content type: Research

    Little is known about diagnostic work-ups or the costs of diagnosing dementia in specialized care. Here, we analyzed the costs of diagnosing dementia according to specific dementia disorders.

    Authors: Bernhard Michalowsky, Steffen Flessa, Johannes Hertel, Olav Goetz, Wolfgang Hoffmann, Stefan Teipel and Ingo Kilimann

    Citation: Alzheimer's Research & Therapy 2017 9:65

    Published on:

  40. Content type: Research

    The present study investigated the relationships between thyroid hormone serum levels or thyroid-stimulating hormone (TSH) and two Alzheimer’s disease (AD)-specific biomarkers, cerebral amyloid beta (Aβ) burde...

    Authors: Hyo Jung Choi, Min Soo Byun, Dahyun Yi, Bo Kyung Sohn, Jun Ho Lee, Jun-Young Lee, Yu Kyung Kim and Dong Young Lee

    Citation: Alzheimer's Research & Therapy 2017 9:64

    Published on:

  41. Content type: Research

    Mixed vascular and neurodegenerative dementia, such as Alzheimer’s disease (AD) with concomitant cerebrovascular disease, has emerged as the leading cause of age-related cognitive impairment. The brain white m...

    Authors: Fang Ji, Ofer Pasternak, Siwei Liu, Yng Miin Loke, Boon Linn Choo, Saima Hilal, Xin Xu, Mohammad Kamran Ikram, Narayanaswamy Venketasubramanian, Christopher Li-Hsian Chen and Juan Zhou

    Citation: Alzheimer's Research & Therapy 2017 9:63

    Published on:

  42. Content type: Review

    The specific amyloid-beta (Aβ) species or other amyloid-precursor protein cleavage products that are most directly related to human neurodegeneration and clinical dementia of the Alzheimer’s type have not yet ...

    Authors: David L. Brody, Hao Jiang, Norelle Wildburger and Thomas J. Esparza

    Citation: Alzheimer's Research & Therapy 2017 9:62

    Published on:

  43. Content type: Research

    Neuropsychological testing is considered crucial for differential diagnosis of Alzheimer’s disease (AD) and behavioural variant frontotemporal dementia (bvFTD). In-depth neuropsychological assessment revealed ...

    Authors: Sophia Reul, Hubertus Lohmann, Heinz Wiendl, Thomas Duning and Andreas Johnen

    Citation: Alzheimer's Research & Therapy 2017 9:61

    Published on:

  44. Content type: Review

    Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer’s disease (AD). It is now recognized that pathophysiological changes begin many years prior to clini...

    Authors: Paul S. Aisen, Jeffrey Cummings, Clifford R. Jack Jr, John C. Morris, Reisa Sperling, Lutz Frölich, Roy W. Jones, Sherie A. Dowsett, Brandy R. Matthews, Joel Raskin, Philip Scheltens and Bruno Dubois

    Citation: Alzheimer's Research & Therapy 2017 9:60

    Published on: